You are here

Inflammation & Immunology Pipeline

Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with rare disease. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.

On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.

 

Immunology Pipeline as of August 1, 2017

  • Discovery Projects
  • Phase 1
    4
  • Phase 2
    6
  • Phase 3
    2
  • Registration
    2
  • Total14
 
Compound Name
Indicationsort ascending
Phase
Submission Type
Compound Type
Xeljanz (tofacitinib)
Therapeutic Area:
Inflammation & Immunology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
JAK Inhibitor
Go to clinical trial
Ulcerative Colitis (U.S.)
Project advanced
Registration Product Enhancement Small Molecule
Xeljanz (tofacitinib)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
JAK Inhibitor
Go to clinical trial
Ulcerative Colitis (E.U.) Phase 3 Product Enhancement Small Molecule
PF-06480605
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
TNFSF15 Blocker
Go to clinical trial
Ulcerative Colitis (Biologic) Phase 2 New Molecular Entity Biologic
Dekavil
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
IL-10
Go to clinical trial
Rheumatoid Arthritis, *Inflammatory Bowel Disease (Biologic) Phase 2 New Molecular Entity Biologic
PF-06650833
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
IRAK4
Go to clinical trial
Rheumatoid Arthritis Phase 2 New Molecular Entity Small Molecule
Xeljanz (tofacitinib)
Therapeutic Area:
Inflammation & Immunology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
JAK Inhibitor
Go to clinical trial
Psoriatic Arthritis (U.S.)
Project advanced
Registration Product Enhancement Small Molecule
Xeljanz (tofacitinib)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
JAK Inhibitor
Go to clinical trial
Psoriatic Arthritis (E.U.) Phase 3 Product Enhancement Small Molecule
PF-06823859
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
interferon, beta 1, fibroblast (IFNB1) Blocker
Go to clinical trial
Lupus (Biologic) Phase 1 New Molecular Entity Biologic
PF-06342674
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
interleukin 7 receptor precursor Modulator
Go to clinical trial
Diabetes Mellitus-Type 1 (Biologic) Phase 1 New Molecular Entity Biologic
PF-06817024
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
Cytokine Modulator
Go to clinical trial
Atopic Dermatitis (Biologic) Phase 1 New Molecular Entity Biologic
PF-04965842
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
JAK Inhibitor
Go to clinical trial
Atopic Dermatitis Phase 2 New Molecular Entity Small Molecule
PF-06651600
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
JAK3
Go to clinical trial
Alopecia Areata, Rheumatoid Arthritis, Ulcerative Colitis Phase 2 New Molecular Entity Small Molecule
PF-06700841
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
TYK2/JAK1
Go to clinical trial
Alopecia Areata, Psoriasis, Ulcerative Colitis Phase 2 New Molecular Entity Small Molecule
PF-06423264
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
acetyl-Coenzyme A carboxylase alpha+beta Inhibitor
Go to clinical trial
Acne Phase 1 New Molecular Entity Small Molecule